MedTrace Logo

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

NCT02279732 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 342

Last updated 2019-08-28

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the life of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.

Conditions

  • Lung Cancer (NSCLC)

Interventions

BIOLOGICAL

Paclitaxel

BIOLOGICAL

Carboplatin

BIOLOGICAL

Ipilimumab

OTHER

Placebo

0.9% sodium chloride injection, USP, or 5% dextrose injection

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-13
Primary Completion
2018-05-03
Completion
2018-05-03

Countries

  • China
  • Germany
  • Hungary
  • Poland
  • Singapore
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02279732 on ClinicalTrials.gov